2. Signaling Pathways
  3. PI3K/Akt/mTOR
    Stem Cell/Wnt
  4. GSK-3
  5. GSK-3β Isoform
  6. GSK-3β Inhibitor

GSK-3β Inhibitor

GSK-3β Inhibitors (69):

Cat. No. Product Name Effect Purity
  • HY-10182
    Laduviglusib
    		Inhibitor 99.76%
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM.
  • HY-12012
    SB 216763
    		Inhibitor 99.30%
    SB 216763 is potent and selective and ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor, with an IC50 value of 34.3 nM for GSK-3α and GSK-3β, respectively.
  • HY-16294
    LY2090314
    		Inhibitor 99.78%
    LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
  • HY-10182A
    Laduviglusib monohydrochloride
    		Inhibitor 99.93%
    Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM.
  • HY-12302
    Kenpaullone
    		Inhibitor 98.01%
    Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.
  • HY-10182G
    Laduviglusib (GMP)
    		Inhibitor
    Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines.
  • HY-120902
    GSK-3β inhibitor 8
    		Inhibitor
    GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of GSK-3β (IC50=64 nM).
  • HY-148561
    CDK8-IN-12
    		Inhibitor
    CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM.
  • HY-10182B
    Laduviglusib trihydrochloride
    		Inhibitor 98.68%
    Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM.
  • HY-10580
    GSK 3 Inhibitor IX
    		Inhibitor 99.74%
    GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
  • HY-10512
    AR-A014418
    		Inhibitor 99.14%
    AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM).
  • HY-14872
    Tideglusib
    		Inhibitor 99.76%
    Tideglusib (NP031112) is an irreversible GSK-3 inhibitor with IC50s of 5 nM and 60 nM for GSK-3βWT (1 h preincubation) and GSK-3βC199A (1 h preincubation), respectively.
  • HY-10590
    TWS119
    		Inhibitor ≥98.0%
    TWS119 is a specific inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
  • HY-59090
    1-Azakenpaullone
    		Inhibitor 99.61%
    1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC50 value of 18 nM.
  • HY-13862
    AZD1080
    		Inhibitor 99.46%
    AZD1080 is a potent and selective GSK3 inhibitor.
  • HY-11012
    TDZD-8
    		Inhibitor 99.81%
    TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
  • HY-B0320A
    Cromolyn sodium
    		Inhibitor 99.10%
    Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic drug.
  • HY-15761
    AZD2858
    		Inhibitor 99.42%
    AZD2858 is a potent, orally active GSK-3 inhibitor, with IC50s of 0.9 and 5 nM for GSK-3α and GSK-3β, respectively, used in the research of fracture healing.
  • HY-12292
    IM-12
    		Inhibitor 98.09%
    IM-12 is an inhibitor of GSK-3β, with an IC50 of 53 nM, and also enhances Wnt signalling.
  • HY-13076
    CHIR-98014
    		Inhibitor ≥98.0%
    CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.